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Abstract
Introduction—The American Heart Association's “Simple 7” offers a practical public health 
conceptualization of cardiovascular health (CVH). CVH predicts incident cardiovascular disease 
(CVD) in younger populations, but has not been studied in a large, diverse population of aging 
postmenopausal women. The extent to which CVH predicts cancer in postmenopausal women is 
unknown.
Methods—Multivariable Cox regression estimated hazard ratios and 95% CIs for the association 
between CVH and incident CVD, any cancer, and cancer subtypes (lung, colorectal, and breast) 
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among 161,809 Women's Health Initiative observational study and clinical trial participants 
followed from 1993 through 2010. Data were analyzed in 2013. CVH score was characterized as 
the number (0 [worst] to 7 [best]) of the American Heart Association's ideal CVH behaviors and 
factors at baseline: smoking, BMI, physical activity, diet, total cholesterol, blood pressure, and 
fasting glucose.
Results—Median follow-up was approximately 13 years. Fewer minorities and less educated 
women achieved ideal CVH, a common benchmark. In adjusted models, compared with women 
with the highest (best) CVH scores, those with the lowest (worst) CVH scores had nearly seven 
times the hazard of incident CVD (6.83, 95% CI=5.83, 8.00), and 52% greater risk of incident 
cancer (1.52, 95% CI=1.35, 1.72). Ideal CVH was most strongly inversely associated with lung 
cancer, then colorectal cancer, and then breast cancer.
Conclusions—Lower ideal CVH is more common among minority and less educated 
postmenopausal women, and predicts increased risk of CVD and cancer in this population, 
emphasizing the importance of prevention efforts among vulnerable older adults.
Introduction
In 2010, the American Heart Association introduced the “Simple 7” cardiovascular health 
(CVH) metric, combining health behaviors (current smoking, BMI, physical activity, and 
healthy diet) and health factors (total cholesterol, blood pressure, and fasting glucose).1 One-
point increases on the CVH scale correspond to a lower risk of mortality (all-cause,2,3 
cardiovascular disease [CVD],2–4 and cancer3,5) and incident CVD,6 stroke,7 and cancer.5 
Community-based studies have used this metric to characterize the prevalence of ideal 
CVH,4,8,9 yet the extent to which the CVH metric predicts CVD and cancer in 
postmenopausal women remains unknown. The authors examined the CVH of a 
geographically and ethnically diverse older population to assess its relationship with incident 
CVD and cancer, including cancer subtypes. Given the immense burden of chronic disease 
in the U.S., the CVH metric may assist public health professionals and healthcare providers 
to improve assessment of risk, direct guideline-based treatment, and augment prevention 
efforts.
Methods
This study used data from the Women's Health Initiative (WHI) observational study and 
clinical trials. The WHI study was overseen by ethics committees at each clinical center and 
the coordinating center; its methods are described thoroughly elsewhere.10,11 Participants 
provided informed consent and contributed data to the current analysis through December 
31, 2010.
Of 161,809 participants, 145,385 had complete CVH data available for analysis. Of those, 
115,306 reported no history of myocardial infarction, stroke, coronary bypass surgery, 
percutaneous transluminal coronary angioplasty, or angina. For cancer outcomes, the 
129,149 women who reported no history of cancer were studied (allowing non-
melanomatous skin cancer).
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Final disease diagnoses, including CVD- or cancer-related deaths, were classified by WHI 
physician adjudicators following review of medical records, death certificates, and autopsy 
reports.12
Time of incident CVD was defined at the first occurrence of myocardial infarction, stroke, 
coronary bypass surgery, percutaneous transluminal coronary angioplasty, angina, or CVD-
related death. Time of incident cancer was defined at the first occurrence of any cancer, 
except non-melanomatous skin cancer, or cancer-related death. Time to incident lung 
(n=1,655), colorectal (n=1,752), and breast (n=7,377) cancer was ascertained.
Measures of CVH appear in Table 1.1 The CVH score represents the number of ideal CVH 
behaviors and factors present at baseline, with a score of 0 as the worst and 7 as the best. All 
CVH data were self-reported at baseline, except for blood pressure and anthropometric 
data.11 Self-reported questions assessed diabetes and cholesterol. If a woman answered yes 
to a history of diabetes or was treated for high blood cholesterol, she was not considered in 
ideal CVH for those metrics.11,12
Whether a woman was an observational study or clinical trial participant was included along 
with age at baseline (50–≤59, 60–≤69, and 70–≥79 years). Race/ethnicity was defined as: 
white (not of Hispanic origin), Hispanic/Latina, black or African American, and other 
(American Indian, Alaska Native, or Asian/Pacific Islander).
Family CVD or cancer history meant an immediate relative had a heart attack, or a female or 
immediate male relative had cancer. Level of education was assigned as the highest grade 
completed in school (less than a high school diploma or GED, equivalent to a high school 
diploma or GED, vocational or some college experience, or a college diploma or higher 
level of education), and marital status as presently married or in a marriage-like relationship, 
or never married, divorced or separated, or widowed.
Baseline characteristics were described and age-adjusted incidence rates for CVD and 
cancer (per 10,000 women) were estimated. The association was evaluated between an ideal 
CVH score and the hazard of incident CVD and cancer, respectively, among those free of 
disease at baseline using Cox regression to estimate age-adjusted and multivariable-adjusted 
hazard ratios and 95% CIs. The ideal CVH score categories 0–1 and 6–7 were collapsed 
owing to sparse data in the worst and best CVH categories.
In the time-to-event analyses, observations were censored for deaths that were not CVD- or 
cancer-related, or if the participant was lost to follow-up. The aforementioned analyses were 
repeated specifically for lung, colorectal, and breast cancers. Analyses were conducted with 
SAS, version 9.2 in 2013.
Results
Women with an ideal CVH score were younger (50–59 years, 47%) and married (69%, 
Table 2). The median length of follow-up among 115,306 women free of CVD at baseline 
was 12.9 years, and among 129,149 women free of cancer at baseline, 12.7 years.
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Approximately 300 women (<1%) had an ideal CVH score of 7 in both CVD- and cancer-
free groups at baseline (data not shown). Among those in ideal CVH, 92% were white 
(Table 2). There were also disparities in CVH by educational attainment; among those in 
ideal CVH, 1% had less than a high school education compared with a high school 
education (9%) and more than a high school education (90%, Table 2).
Age-adjusted rates of incident CVD steadily decreased with increasing number of CVH 
behaviors and factors at ideal levels (Figure 1). The multivariable-adjusted hazard of CVD 
was inversely related to the ideal CVH score (Figure 2). Characteristics associated with 
lower CVD risk in the fully adjusted model included: younger age (50–59 years, 0.24, 95% 
CI=0.23, 0.25; 60–69 years, 0.54, 95% CI=0.53, 0.55), being married or partnered (0.84, 
95% CI=0.82, 0.85), and having no family history of CVD (0.76, 95% CI=0.74, 0.77).
Rates of incident cancer decreased with increasing number of CVH behaviors at ideal levels 
with no clear dose–response trend in a favorable direction across strata of increasing CVH 
factors (Figure 1). The multivariable-adjusted hazard of cancer was also inversely related to 
ideal CVH score (Figure 2). Characteristics associated with lower cancer risk included: 
younger age (50–59 years, 0.63, 95% CI=0.62, 0.64; 60–69 years, 0.84, 95% CI=0.83, 0.86), 
Hispanic/Latina descent (0.85, 95% CI=0.79, 0.90), being married or partnered (0.94, 95% 
CI=0.93, 0.96), and no family history of cancer (0.88, 95% CI=0.87, 0.90).
Lung and colorectal cancers exhibited stronger inverse associations with the ideal CVH 
score than did breast cancer (Figure 2).
Discussion
A favorable risk factor and behavior profile, as expressed by a higher ideal CVH score, 
predicts a lower risk of CVD and cancer in postmenopausal women. The magnitude of effect 
of ideal CVH score was more pronounced for CVD than cancer. Among cancers, ideal CVH 
was most strongly inversely related to lung cancer, followed by colorectal and finally breast 
cancer.
The uniquely large sample of postmenopausal women in WHI supported minority subgroup 
analyses, and ideal CVH for five or more of the seven behaviors and factors was lowest 
among African Americans (9%), followed by Hispanic/Latinas (17%), other races (24%), 
and whites (27%). Unadjusted analyses also underscored the clear relationship between 
higher educational attainment and higher CVH health score.
Limitations
Self-reported CVH data and this study's definition of ideal CVH for fasting blood glucose 
and cholesterol factors reflect the limitations of the data set, and may have misclassified 
some women for these particular metrics. Also, this work focused only on ideal CVH. More 
research is needed to capture the broader spectrum of CVH and its effects on the primary, 
secondary, and ertiary prevention of CVD and cancer.
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Conclusions
This study adds to the growing literature linking ideal CVH to chronic diseases, and 
emphasizes the need for providers who care for older patients, particularly those with 
sociodemographic vulnerabilities, to address CVH.
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Figure 1. 
Age-adjusted incidence rate (per 100 women) of CVD (left) and cancer (right), according to 
the number of ideal CVH factors (total cholesterol, blood pressure, glucose) and behaviors 
(smoking, BMI, physical activity, healthy diet score): WHI study participants.
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Figure 2. 
Multivariable-adjusted hazard ratios and 95% CI for incident CVD and cancer (left), and 
cancer subtypes (right), including death, by ideal CVH score: WHI study participants. Full 
models are adjusted for OS/CT enrollment, age, race/ethnicity, marital status, education, and 
family history of CVD or cancer, respectively.
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Table 1
Measures of CVH: 4 Health Behaviors and 3 Health Factors1
Poor health Intermediate health Ideal health
Health behaviors
 Smoking status Yes Former ≤12 months Never or quit >12 months
 BMI ≥30 kg/m2 25-29.9 kg/m2 <25 kg/m2
 Physical activity None
1-149 min/wk moderate or 1-74 min/wk 
vigorous or 1-149 min/wk moderate + 
vigorous
≥150 min/wk moderate or ≥ 75 
min/wk vigorous or ≥150 min/wk 
moderate + vigorous
 Healthy diet scorea 0–1 components 2–3 components 4–5 components
Health factors
 Total cholesterol ≥240 mg/dL 200-239 mg/dL or treated to goal <200 mg/dL
 Blood pressure Systolic ≥140 mm Hg or Diastolic ≥90 mm Hg
Systolic 120-139 mm Hg or Diastolic 80-89 
mm Hg or treated to goal
Systolic <120 mm Hg Diastolic 
<80 mm Hg
 Fasting plasma glucose ≥126 mg/dL 100-125 mg/dL or treated to goal <100 mg/dL
aOne point for each of the following healthy diet score components: ≥4.5 cups/day of fruits and vegetables; ≥2 3.5-ounce servings/week of fish; ≥3 
1-ounce servings/day of whole grains; <1,500 mg/day of sodium; and ≤36 ounces/week of sugar-sweetened beverages.
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